Efficacy and safety of daclatasvir‐based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

Summary Direct‐acting antiviral agents (DAA) combining daclatasvir (DCV) have reported good outcomes in the recurrence of hepatitis C virus (HCV) infection after liver transplant (LT). However, its effect on the severe recurrence and the risk of death remains controversial. We evaluated the efficacy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplant international 2017-10, Vol.30 (10), p.1041-1050
Hauptverfasser: Salcedo, Magdalena, Prieto, Martín, Castells, Lluís, Pascasio, Juan Manuel, Montero Alvarez, Jose Luis, Fernández, Inmaculada, Sánchez‐Antolín, Gloria, González‐Diéguez, Luisa, García‐Gonzalez, Miguel, Otero, Alejandra, Lorente, Sara, Espinosa, Maria Dolores, Testillano, Milagros, González, Antonio, Castellote, Jose, Casafont, Fernando, Londoño, Maria‐Carlota, Pons, Jose Antonio, Molina Pérez, Esther, Cuervas‐Mons, Valentín, Pascual, Sonia, Herrero, Jose Ignacio, Narváez, Isidoro, Vinaixa, Carmen, Llaneras, Jordi, Sousa, Jose Manuel, Bañares, Rafael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!